BioCryst Pharmaceuticals vs Travere Therapeutics
BCRX and TVTX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BCRX and TVTX compare
Travere Therapeutics is the larger company, worth 2.5 times as much as BioCryst Pharmaceuticals ($4.8B against $1.9B).
BioCryst Pharmaceuticals grew revenue faster over the last twelve months (60.3% versus 49.4% for Travere Therapeutics).
Travere Therapeutics keeps more of each dollar of sales as profit, with a net margin of −18.7% compared with −37.4% at BioCryst Pharmaceuticals.
BioCryst Pharmaceuticals scores higher on the StockData Score (9 against 6 for Travere Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BCRX | TVTX |
|---|---|---|
| Size and price | ||
| Market cap | $1.9B | $4.8B |
| Share price | $7.61 | $50.65 |
| Change, 1 year | 6.0% | 38.9% |
| Change, 5 years | −36.0% | 73.0% |
| Beta (5Y) | 0.79 | 1.14 |
| Employees | 435 | 497 |
| StockData Score | ||
| Total score | 9 (better) | 6 |
| Valuation score | 1 (better) | 0 |
| Growth score | 4 (better) | 3 |
| Performance score | 2 | 2 |
| Health score | 2 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 2.0× (better) | 7.3× |
| P/B | – | 211× |
| P/FCF | 5.3× | – |
| FCF yield | 18.8% | – |
| Growth | ||
| Revenue growth (TTM) | 60.3% (better) | 49.4% |
| Revenue growth, 5Y average | 118% (better) | 19.9% |
| Profitability | ||
| Gross margin | 97.9% | 98.5% (better) |
| Operating margin | −30.1% | −20.5% (better) |
| Net margin | −37.4% | −18.7% (better) |
| FCF margin | 38.0% | – |
| Return on equity | – | −253% |
| Financial health | ||
| Interest coverage | −3.8× (better) | −15.1× |
| Current ratio | 2.71 | 3.00 (better) |
| Altman Z-score | −3.13 | 1.68 (better) |
| Piotroski F-score | 7 | 7 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 103% | 112% |
| Held by insiders | 1.9% | 1.6% |
| Insider net buying, 12 months | −$4.1M (better) | −$110M |
| Short interest, % of float | 11.0% | 10.3% |
Go deeper
- BCRX stock overview
- BCRX income statement
- BCRX valuation and score
- TVTX stock overview
- TVTX income statement
- TVTX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.